MarcRyanMatranaMD

Genitourinary Oncology, Hematologic Oncology

Medical Director, Ochsner Precision Cancer Therapies Program; Senior Lecturer, University of Queensland School of Medicine/Ochsner Clinical School; Core Faculty, Ochsner Internal Medicine Residency Program

Join to view full profile

Dr. Matrana is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Matrana's full profile

Already have an account?

Office
1514 Jefferson Hwy
New Orleans, LA 70121
Phone+1 504-842-3910

Fax+1 504-842-4533

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Ochsner Clinic FoundationChief Residency, Internal Medicine, 2009 - 2010
Ochsner Clinic FoundationResidency, Internal Medicine, 2006 - 2009
Louisiana State University School of Medicine in New OrleansClass of 2006
Tulane UniversityM.S., Human Genetics, 2001 - 2002

Certifications & Licensure

LA State Medical License 2007 - 2025
MS State Medical License 2020 - 2025
TX State Medical License 2010 - 2025
AL State Medical License 2020 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Young Alumnus of the Year Tulane University, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Start of enrollment: 2015 Aug 27
Completed
Phase 2
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Start of enrollment: 2016 Apr 10
Terminated
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

11 citations
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations...
Matteo Santoni, Francesco Massari, Zin W Myint, Roberto Iacovelli, Martin Pichler
Clinical Genitourinary Cancer. 2023-10-01
15 citations
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Matteo Santoni, Francesco Massari, Zin W Myint, Roberto Iacovelli, Martin Pichler
Targeted Oncology. 2023-07-01
17 citations
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Crit...
Matteo Santoni, Sebastiano Buti, Zin W Myint, Marco Maruzzo, Roberto Iacovelli
European Urology Oncology. 2024-02-01

Lectures

No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Ochsner Health Advances Precision Medicine, Becomes National Leader in Universal Genomic Testing for ChemotherapyMarch 16th, 2023
How Oschner Is Leading the Curve with Universal Genome Testing for ChemoFebruary 17th, 2023
AstraZeneca Announces Winners of Fourth Annual Cancer Community AwardsOctober 20th, 2022
Join now to see all